Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANEXSIA vs ABILIFY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.
Partial agonist at dopamine D2 and serotonin 5-HT1A receptors; antagonist at serotonin 5-HT2A receptors.
Relief of moderate to moderately severe pain
Schizophrenia,Bipolar I disorder (acute manic/mixed episodes, maintenance),Major depressive disorder (adjunctive therapy),Irritability associated with autistic disorder,Tourette's disorder
50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.
Schizophrenia: 10-15 mg once daily (max 30 mg). Bipolar mania: 15-30 mg once daily (as monotherapy or adjunct). Adjunctive MDD: 2-5 mg once daily, titrating to 5-10 mg. Autism irritability: 2 mg/day initially, titrated to 5-10 mg/day (max 15 mg/day).
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (Cr Cl <30 m L/min).
Aripiprazole: 75 hours; dehydro-aripiprazole: 94 hours. Steady-state reached in ~14 days.
Hydrocodone is metabolized via CYP2D6 and CYP3A4 to hydromorphone and norhydrocodone. Acetaminophen is primarily metabolized via hepatic glucuronidation and sulfation; a minor pathway via CYP2E1 produces NAPQI, which is detoxified by glutathione.
Hepatic metabolism primarily via CYP3A4 and CYP2D6; also by dehydrogenation and N-dealkylation.
Approximately 70% renal (unchanged drug and metabolites), 20% biliary/fecal, 10% other.
Renal (25% unchanged, 18% as dehydro-aripiprazole) and fecal (55% unchanged and metabolites).
Approximately 95% bound to plasma albumin and alpha-1-acid glycoprotein.
>99% bound to albumin and alpha-1-acid glycoprotein.
0.2-0.4 L/kg, indicating limited extravascular distribution primarily confined to plasma and interstitial fluid.
4.9 L/kg (high distribution into tissues).
Oral: 80-90%; Intramuscular: 90-100%; Rectal: 70-80%.
Oral: 87% (tablet and solution); IM: 100%.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 50% dose reduction; GFR <15 m L/min: avoid use.
No dosage adjustment required for renal impairment; not removed by hemodialysis.
Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: avoid use.
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh class C) due to limited data.
1-2 mg/kg/dose orally every 6 hours; maximum 6 mg/kg/day.
Schizophrenia (13-17 years): 2 mg/day, target 10-25 mg/day. Bipolar mania (10-17 years): 2 mg/day, target 10-30 mg/day. Autism irritability (6-17 years): 2 mg/day, target 5-15 mg/day.
Initiate at 25 mg every 6 hours; increase cautiously; monitor renal function.
Initiate at lower doses (e.g., 2-5 mg/day) and titrate slowly due to increased risk of adverse effects, especially orthostatic hypotension and cognitive decline.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity from acetaminophen.
Increased risk of death in elderly patients with dementia-related psychosis due to cerebrovascular events.
Risk of respiratory depression, especially in elderly or debilitated patients; adrenal insufficiency; severe hypotension; seizures; opioid-induced hyperalgesia; acetaminophen hepatotoxicity (avoid exceeding 4 g/day); serotonin syndrome if used with serotonergic agents.
Increased mortality in elderly dementia patients, suicidal thoughts/behaviors, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes (hyperglycemia, dyslipidemia, weight gain), orthostatic hypotension, leukopenia/neutropenia, seizures, body temperature dysregulation, dysphagia, impulse control disorders.
Hypersensitivity to hydrocodone or acetaminophen; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting; known or suspected GI obstruction; severe hepatic impairment; concomitant use of MAOIs or within 14 days.
Known hypersensitivity to aripiprazole or any of its excipients.
Avoid alcohol; may increase risk of hepatotoxicity and GI bleeding. Limit caffeine intake from coffee, tea, cola, or energy drinks due to added caffeine content. High-fat meals may delay absorption; take on empty stomach for faster onset if tolerated.
Grapefruit juice may increase aripiprazole exposure; avoid concurrent intake. No other significant food interactions. Alcohol can enhance CNS depression; limit or avoid.
First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus arteriosus and oligohydramnios due to fetal renal effects; avoid use after 30 weeks gestation.
Pregnancy category C. First trimester: risk of major malformations not significantly increased based on limited data; however, neurodevelopmental effects uncertain. Second and third trimesters: neonates exposed in late pregnancy are at risk for extrapyramidal symptoms (EPS) and withdrawal syndrome including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder.
Excreted into breast milk in low concentrations (M/P ratio not established). Not recommended during breastfeeding due to potential for adverse effects in the infant, including renal impairment and gastrointestinal bleeding.
Aripiprazole is excreted in human breast milk; milk-to-plasma (M/P) ratio is approximately 0.5 to 1.0. Relative infant dose is estimated to be 1-3% of maternal weight-adjusted dose. Limited data; use with caution. Monitor infant for sedation, poor feeding, and abnormal movements.
Dose adjustment not generally required; however, due to increased renal clearance in pregnancy, shortened dosing intervals may be necessary for sustained efficacy. Use lowest effective dose for shortest duration.
No established pharmacokinetic data; however, pregnancy-induced physiological changes (increased plasma volume, renal clearance) may lower aripiprazole levels. Monitor therapeutic efficacy and consider dose adjustment if symptom exacerbation. No specific dose modification guidelines available; titrate based on clinical response and tolerability.
ANEXSIA is a combination analgesic containing paracetamol, ibuprofen, and caffeine. It is contraindicated in patients with active peptic ulcer disease, severe hepatic impairment, or hypersensitivity to NSAIDs. Avoid concurrent use with other NSAIDs or paracetamol-containing products. Monitor renal function in elderly or dehydrated patients. Caffeine may exacerbate anxiety or insomnia.
Abilify (aripiprazole) is a partial dopamine agonist, which reduces the risk of extrapyramidal symptoms and hyperprolactinemia compared to full antagonists. Monitor for akathisia, especially during dose titration. QT prolongation risk is lower than with other antipsychotics; use caution in patients with cardiac disease. Avoid use in dementia-related psychosis due to increased mortality. Therapeutic effects may take 2-4 weeks; full response often requires 6-8 weeks.
Do not exceed recommended dose; overdosage of paracetamol can cause liver damage.,Take with food or milk to reduce gastrointestinal upset.,Avoid alcohol while taking this medication to reduce risk of liver toxicity and GI bleeding.,Discontinue use and consult if signs of allergic reaction, GI bleeding, or liver problems occur.,Caffeine may cause nervousness, insomnia, or increased heart rate; limit caffeine-containing foods and beverages.
Take exactly as prescribed; do not stop abruptly without consulting your doctor.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Avoid alcohol and grapefruit juice as they can alter drug levels.,Report any uncontrolled muscle movements, especially in face or tongue.,Monitor weight and blood glucose regularly as it can cause metabolic changes.,If you miss a dose, take it as soon as you remember unless it's almost time for the next dose; do not double up.,Use effective contraception if of childbearing potential; discuss pregnancy plans with your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANEXSIA vs ABILIFY, answered by our medical review team.
ANEXSIA is a Opioid Analgesic Combination that works by ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.. ABILIFY is a Atypical antipsychotic that works by Partial agonist at dopamine D2 and serotonin 5-HT1A receptors; antagonist at serotonin 5-HT2A receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANEXSIA and ABILIFY depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANEXSIA is: 50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.. The standard adult dose of ABILIFY is: Schizophrenia: 10-15 mg once daily (max 30 mg). Bipolar mania: 15-30 mg once daily (as monotherapy or adjunct). Adjunctive MDD: 2-5 mg once daily, titrating to 5-10 mg. Autism irritability: 2 mg/day initially, titrated to 5-10 mg/day (max 15 mg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANEXSIA and ABILIFY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANEXSIA is classified as Category C. First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus . ABILIFY is classified as Category C. Pregnancy category C. First trimester: risk of major malformations not significantly increased based on limited data; however, neurodevelopmental effects uncertain. Second and thir. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.